Global Cell and Gene Therapy Manufacturing Market Report 2024-2034 - A $124.45 Billion Opportunity with Roche, Hitachi Chemical, and Thermo Fisher Scientific Dominating
June 14, 2024 06:16 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Manufacturing Market Analysis & Forecast 2024-2034" report has been added to ResearchAndMarkets.com's offering.The...
CRISPR Therapies Market Research 2024: Pipeline Analysis, Therapeutic Assessment, Unmet Needs, Impact of Drugs
June 14, 2024 06:15 ET
|
Research and Markets
Dublin, June 14, 2024 (GLOBE NEWSWIRE) -- The "CRISPR therapies - Pipeline Insight, 2024" drug pipelines has been added to ResearchAndMarkets.com's offering.This "CRISPR Therapies - Pipeline...
Cell and Gene Therapy Industry Analysis of Deal Activity from 2021 to 2024: Specific Details of 2000+ CGT Deals with Regional Breakdown of Dealmaking
June 10, 2024 11:50 ET
|
Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Deals Analysis, 2021-2024" report has been added to ResearchAndMarkets.com's offering. The Cell and Gene Therapy Deals...
$43+ Billion Cell and Gene Therapy Clinical Trials Market Forecast, 2024-2034, by Therapy Type, Phase, Indication, and Region
June 05, 2024 03:41 ET
|
Research and Markets
Dublin, June 05, 2024 (GLOBE NEWSWIRE) -- The "Global Cell and Gene Therapy Clinical Trials Market Analysis & Forecast to 2024-2034" report has been added to ResearchAndMarkets.com's...
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
May 31, 2024 08:36 ET
|
Ocugen
Established Medium Dose as Safe and Tolerable Dose in Current OCU410 Clinical TrialDSMB Recommends Continuing with High-Dose Cohort Dosing with Concurrent Phase 2 Dosing MALVERN, Pa., May 31, 2024 ...
Ocugen to Present at BIO International Convention 2024
May 29, 2024 07:15 ET
|
Ocugen
MALVERN, Pa., May 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
May 29, 2024 07:00 ET
|
Fractyl Health, Inc.
Fractyl Health to Present New Preclinical Obesity Data from Rejuva® Platform at the American Diabetes Association’s 84th Scientific Sessions
Ocugen Set to Join Russell 3000® Index Effective June 28, 2024
May 28, 2024 07:02 ET
|
Ocugen
MALVERN, Pa., May 28, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Global Cell and Gene Therapy (CGT) Supply Chain Software Markets, 2019-2023 & 2024-2035: Companies Enter Strategic Collaborations to Meet Growing Demand, Opportunities in Expanding Product Portfolios
May 22, 2024 05:03 ET
|
Research and Markets
Dublin, May 22, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapy Supply Chain Software Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Process Component, Type of...
Ocugen Announces CSO to Present on Modifier Gene Therapy at International Society for Cell & Gene Therapy 2024
May 20, 2024 07:00 ET
|
Ocugen
MALVERN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...